Background: Perioperative treatment is a gold standard in locally advanced gastric cancer or GEJ cancer in the Western population. Unfortunately, the response rate after neoadjuvant chemotherapy (NAC) remains limited. Moreover, there are currently no biomarkers enabling an individual prediction of therapeutic efficacy. The aim of this study was the identification of serum biomarkers of early response to NAC. Methods: We conducted this prospective study in the MSCNRIO in Warsaw, Poland. A total of 71 patients and 15 healthy volunteers gave informed consent. Complete blood count, carcinoembryonic antigen (CEA), carcinoma antigen 125 (CA125), carcinoma antigen 19.9 (CA19.9), and fibrinogen (F) were measured at baseline and before every cycle. Circulating tumour cells (CTCs) and interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-8 (IL-8), and interleukin-10 (IL-10) were measured in a pilot group of 40 patients at baseline and before cycle two (C2) and cycle three (C3). Results: Of all the measured parameters, only the IL-6 serum level was statistically significant. The IL-6 level before C2 of chemotherapy was significantly decreased in the complete pathological response (pCR) vs. the non-pCR group (3.71 pg/mL vs. 7.63 pg/mL,p= 0.004). In all patients with an IL-6 level below 5.0 pg/mL in C2, tumour regression TRG1a/1b according to the Becker classification and ypN0 were detected in postoperative histopathological specimens. The IL-6 level before C1 of chemotherapy was significantly elevated in ypN+ vs. ypN0 (7.69 pg/mL vs. 2.89 pg/mL,p= 0.022). Conclusions: The trial showed that an elevated level of IL-6 prior to treatment and C2 might be a predictor of pathological response to NAC.
背景：围手术期治疗是西方人群局部进展期胃癌或胃食管结合部癌的金标准。然而，新辅助化疗（NAC）后的应答率仍然有限。此外，目前尚无能够个体化预测疗效的生物标志物。本研究旨在鉴定NAC早期应答的血清生物标志物。 方法：我们在波兰华沙的MSCNRIO进行了这项前瞻性研究。共有71名患者和15名健康志愿者签署了知情同意书。在基线和每个周期前测量了全血细胞计数、癌胚抗原（CEA）、癌抗原125（CA125）、癌抗原19.9（CA19.9）和纤维蛋白原（F）。在40名患者的试点组中，于基线、第二周期（C2）前和第三周期（C3）前测量了循环肿瘤细胞（CTCs）以及白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）和白细胞介素-10（IL-10）。 结果：在所有测量的参数中，仅IL-6血清水平具有统计学意义。在完全病理缓解（pCR）组与非pCR组中，化疗C2前的IL-6水平显著降低（3.71 pg/mL vs. 7.63 pg/mL，p=0.004）。在所有C2时IL-6水平低于5.0 pg/mL的患者中，术后组织病理学标本中检测到根据Becker分类的肿瘤退缩TRG1a/1b和ypN0。在ypN+组与ypN0组中，化疗C1前的IL-6水平显著升高（7.69 pg/mL vs. 2.89 pg/mL，p=0.022）。 结论：该试验表明，治疗前和C2前IL-6水平升高可能是NAC病理应答的预测因子。
肿瘤(癌症)患者之家